NasdaqCM:HSDT

Stock Analysis Report

Helius Medical Technologies

Executive Summary

Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, or acquiring noninvasive technologies for the treatment of symptoms caused by neurological disease or trauma.

Snowflake

Fundamentals

Mediocre balance sheet with limited growth.

Risks

  • Helius Medical Technologies has significant price volatility in the past 3 months.
  • Helius Medical Technologies is covered by less than 3 analysts.

Share Price & News

How has Helius Medical Technologies's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

3.8%

NasdaqCM:HSDT

-0.9%

US Medical Equipment

1.3%

US Market


1 Year Return

-80.7%

NasdaqCM:HSDT

9.1%

US Medical Equipment

2.0%

US Market

HSDT underperformed the Medical Equipment industry which returned 8.7% over the past year.

HSDT underperformed the Market in United States of America which returned 1.7% over the past year.


Share holder returns

HSDTIndustryMarket
7 Day3.8%-0.9%1.3%
30 Day-10.7%0.7%3.9%
90 Day-34.2%4.4%3.4%
1 Year-80.7%-80.7%10.0%9.1%4.2%2.0%
3 Year-62.7%-62.7%70.7%65.5%47.2%37.6%
5 Year-83.6%-83.6%130.7%104.3%60.5%42.9%

Price Volatility Vs. Market

How volatile is Helius Medical Technologies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Helius Medical Technologies undervalued based on future cash flows and its price relative to the stock market?

3.89x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Helius Medical Technologies to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Helius Medical Technologies to establish if it is available at substantial discount.


Price Based on Earnings

Helius Medical Technologies is loss making, we can't compare its value to the US Medical Equipment industry average.

Helius Medical Technologies is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Helius Medical Technologies, we can't assess if its growth is good value.


Price Based on Value of Assets

Helius Medical Technologies is good value based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Helius Medical Technologies expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

-43.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Helius Medical Technologies's revenue is expected to grow significantly at over 20% yearly.

Helius Medical Technologies is not considered high growth as it is expected to be loss making for the next 1-3 years.

Helius Medical Technologies's revenue growth is expected to exceed the United States of America market average.

Unable to compare Helius Medical Technologies's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.

Unable to compare Helius Medical Technologies's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Helius Medical Technologies will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Helius Medical Technologies performed over the past 5 years?

-30.9%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Helius Medical Technologies does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Helius Medical Technologies's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Helius Medical Technologies's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Helius Medical Technologies has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Helius Medical Technologies has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Helius Medical Technologies improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Helius Medical Technologies's financial position?


Financial Position Analysis

Helius Medical Technologies is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Helius Medical Technologies's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Helius Medical Technologies's level of debt (0%) compared to net worth is satisfactory (less than 40%).

Unable to establish if Helius Medical Technologies's debt level has increased without past 5-year debt data.


Balance Sheet

Low level of unsold assets.

Debt is not covered by short term assets, assets are -1.4887999648161E+17x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Helius Medical Technologies has less than a year of cash runway based on current free cash flow.

Helius Medical Technologies has less than a year of cash runway if free cash flow continues to grow at historical rates of 30% each year.


Next Steps

Dividend

What is Helius Medical Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Helius Medical Technologies's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Helius Medical Technologies's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Helius Medical Technologies has not reported any payouts.

Unable to verify if Helius Medical Technologies's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Helius Medical Technologies has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Helius Medical Technologies's salary, the management and board of directors tenure and is there insider trading?

4.3yrs

Average management tenure


CEO

Phil Deschamps (57yo)

5.3yrs

Tenure

US$1,394,760

Compensation

Mr. Philippe Deschamps, also known as Phil, has been the Chief Executive Officer and President of Helius Medical Technologies, Inc. since June 13, 2014. Mr. Deschamps served as the Chief Executive Officer  ...


CEO Compensation Analysis

Phil's remuneration is higher than average for companies of similar size in United States of America.

Phil's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

4.3yrs

Average Tenure

57yo

Average Age

The tenure for the Helius Medical Technologies management team is about average.


Board Age and Tenure

4.8yrs

Average Tenure

57yo

Average Age

The tenure for the Helius Medical Technologies board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Jonathan Sackier (61yo)

    Chief Medical Officer

    • Tenure: 4.8yrs
    • Compensation: US$1.31m
  • Brian Bapty (50yo)

    Vice President of Strategy and Business Development

    • Tenure: 3.9yrs
  • Phil Deschamps (57yo)

    Chairman

    • Tenure: 5.3yrs
    • Compensation: US$1.39m
  • Joyce LaViscount (57yo)

    CFO & COO

    • Tenure: 3.9yrs
    • Compensation: US$1.10m
  • Diane Carman

    Secretary

    • Tenure: 0yrs

Board Members

  • Ed Straw (80yo)

    Independent Director

    • Tenure: 4.8yrs
    • Compensation: US$89.53k
  • Scott Parazynski (59yo)

    Member of Scientific Advisory Board

    • Tenure: 4.8yrs
  • Huaizheng Peng (57yo)

    Director

    • Tenure: 3.8yrs
    • Compensation: US$89.53k
  • Tom Griffin (56yo)

    Director

    • Tenure: 3.1yrs
    • Compensation: US$107.43k
  • Phil Deschamps (57yo)

    Chairman

    • Tenure: 5.3yrs
    • Compensation: US$1.39m
  • Dane Andreeff (53yo)

    Director

    • Tenure: 2.1yrs
    • Compensation: US$107.43k
  • Carl Hauser

    Member of Scientific Advisory Board

    • Tenure: 4.8yrs
  • Mitch Tyler (66yo)

    Director

    • Tenure: 5.3yrs
    • Compensation: US$122.11k
  • Catherine Cho

    Member of Scientific Advisory Board

    • Tenure: 4.8yrs
  • Robert Walter (49yo)

    Independent Director

    • Tenure: 3.8yrs
    • Compensation: US$107.43k

Company Information

Helius Medical Technologies, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Helius Medical Technologies, Inc.
  • Ticker: HSDT
  • Exchange: NasdaqCM
  • Founded:
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$49.735m
  • Shares outstanding: 25.90m
  • Website: https://heliusmedical.com

Number of Employees


Location

  • Helius Medical Technologies, Inc.
  • 642 Newtown Yardley Road
  • Suite 100
  • Newtown
  • Pennsylvania
  • 18940
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
HSMTSX (The Toronto Stock Exchange)YesClass A Common SharesCACADJul 2014
HSDTNasdaqCM (Nasdaq Capital Market)YesClass A Common SharesUSUSDJul 2014
26H1DB (Deutsche Boerse AG)YesClass A Common SharesDEEURJul 2014

Biography

Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, or acquiring noninvasive technologies for the treatment of symptoms caused by neurological disease or trauma. ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/16 00:22
End of Day Share Price2019/09/13 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.